Eagle Global Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-8,565
| Closed | -$281K | – | 246 |
|
|
2022
Q1 | $281K | Sell |
8,565
-3,520
| -29% | -$115K | 0.02% | 205 |
|
|
2021
Q4 | $319K | Sell |
12,085
-47,690
| -80% | -$1.26M | 0.02% | 201 |
|
|
2021
Q3 | $6.01M | Buy |
59,775
+25,420
| +74% | +$2.56M | 0.4% | 70 |
|
|
2021
Q2 | $4.86M | Buy |
34,355
+8,550
| +33% | +$1.21M | 0.31% | 82 |
|
|
2021
Q1 | $2.57M | Buy |
25,805
+1,015
| +4% | +$101K | 0.19% | 96 |
|
|
2020
Q4 | $3.07M | Buy |
24,790
+2,810
| +13% | +$347K | 0.24% | 88 |
|
|
2020
Q3 | $2.14M | Buy |
21,980
+2,480
| +13% | +$242K | 0.19% | 95 |
|
|
2020
Q2 | $3.04M | Buy |
19,500
+11,450
| +142% | +$1.79M | 0.27% | 83 |
|
|
2020
Q1 | $1.16M | Buy |
8,050
+550
| +7% | +$79.4K | 0.12% | 118 |
|
|
2019
Q4 | $1.53M | Hold |
7,500
| – | – | 0.08% | 133 |
|
|
2019
Q3 | $602K | Hold |
7,500
| – | – | 0.03% | 154 |
|
|
2019
Q2 | $708K | Buy |
7,500
+1,100
| +17% | +$104K | 0.03% | 155 |
|
|
2019
Q1 | $547K | Buy |
6,400
+400
| +7% | +$34.2K | 0.02% | 165 |
|
|
2018
Q4 | $337K | Buy |
+6,000
| New | +$337K | 0.01% | 181 |
|